Clinical trial
A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the…
NCT00266604 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00266604 |
|---|---|
| Title | A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy |
| Official title | TOPAMAX (Topiramate) Initiated as Monotherapy in Epilepsy (TIME): A Multicenter, Outpatient, Open-Label, Study to Evaluate the Dosing, Effectiveness and Safety of TOPAMAX as Monotherapy in the Treatment of Epilepsy in Clinical Practice |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Ortho-McNeil Neurologics, Inc. Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Epilepsy, Seizures, Epilepsies, Partial, Generalized, Tonic-Clonic |
| Intervention type | Drug |
| Interventions | Topiramate |
| Enrollment | 409 |
| Start date | Dec 1, 2005 |
| Completion | Jun 1, 2007 |
| First posted | Dec 19, 2005 |
| Last update posted | Jun 10, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: